IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer

CAESAREA, Israel and CLEVELAND, Oct. 1, 2013 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) announced today that it received its first order for cryoablation systems to be used in a clinical study for treatment of lung cancer tumors. The study will take place at the Kameda Medical Center in Kamogawa City, Japan. The cryoablation systems and probes are based on IceSense3™ technology.  Currently the IceSense3™ system is being studied in the same center for the treatment of small breast cancer tumors.

(Photo: http://photos.prnewswire.com/prnh/20130507/CL09547 )

Cryoablation is the technique of using extreme cold to destroy tissue.  It has been used for years in medical applications such as dermatology, kidney, prostate and liver to treat both cancerous and non-cancerous tumors.

"This study, which is fully funded by Kameda Medical Center, may pave the road for IceCure to also use its cryoablation systems for the treatment of lung cancer tumors in addition to the current commercial applications for the treatment of benign breast tumors and investigational use for small breast cancers," stated Hezi Himelfarb, President and CEO of IceCure Medical.  "According to the American Cancer Society, lung cancer is the leading cancer killer of both men and women in the United States, more than the next three cancers combined (colon, breast and prostate). An estimated 160,340 Americans were expected to die from lung cancer in 2012, accounting for approximately 28 percent of all cancer deaths."

"It is important to mention that an animal study conducted last July using IceCure's system, has shown better results when compared with other cryoablation systems. Successful results in the Japanese trial may open the possibility to enter a huge market with hundreds of thousands of new cases every year. We continue our marketing and sales efforts in the U.S. for the treatment of (benign) breast fibroadenoma, as well as the clinical studies for treating breast cancer tumors in Japan and the U.S," added Himelfarb.

The clinical study will be managed by Dr. Akihiko Takeshi, the chairman of the Thoracic Surgery Department at Kameda Medical Center and will be funded by the hospital. After analyzing the results, the company will decide its future involvement in the treatment of lung cancer tumors using its cryoablation technology.

Eisuke Fukuma, MD, PhD, Chairman of Breast Center at Kameda Medical Center in Kamogawa City, Japan has been developing cryoablation under image-guidance as a nonsurgical treatment for small breast cancer since 2006. Dr. Fukuma's most recent 20 patients added to the clinical trial were treated using IceCure Medical's IceSense3™ cryoablation system.

While mainstream cancer treatment still requires significant research, the IceSense3 system is widely available in the U.S. for the treatment of benign breast disease.  The procedure usually takes about 10-15 minutes, with no pain and virtually no scar (no sutures are required). As with a needle biopsy, many women can return to work or their normal activity quickly.

The IceSense3™ Cryoablation System was designed for efficient and effective treatment of breast tumors. The system has 510k FDA-approval for benign and malignant breast disease.

About IceCure Medical

IceCure Medical, is a medical device company focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's health. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. The company was founded in 2006 with main offices in Caesarea, Israel and U.S. headquarters in Cleveland, Ohio. For more information, visit www.icecure-medical.com.  

For more information, contact
Will Irby
IceCure Medical, Inc.
(901) 237-4630
[email protected]

SOURCE IceCure Medical, Inc.